12:00 AM
 | 
Sep 24, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ALX-0171: Phase I data

A double-blind, placebo-controlled, Dutch Phase I trial in 60 healthy males showed that single ascending-doses of 2.1-210 mg ALX-0171 (n=44) and multiple ascending-doses of twice-daily 140 and 210 mg ALX-0171 for...

Read the full 133 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >